|1.||Mashima, Yukihiko: 4 articles (06/2013 - 01/2004)|
|2.||Nakazawa, Mitsuru: 3 articles (06/2013 - 01/2002)|
|3.||Sugawara, Takeshi: 3 articles (06/2013 - 12/2012)|
|4.||Yamamoto, Shuichi: 3 articles (06/2013 - 12/2012)|
|5.||Nao-I, Nobuhisa: 2 articles (06/2013 - 12/2012)|
|6.||Murakami, Akira: 2 articles (06/2013 - 12/2012)|
|7.||Machida, Shigeki: 2 articles (06/2013 - 12/2012)|
|8.||Wada, Yuko: 2 articles (06/2013 - 12/2012)|
|9.||Toris, Carol B: 2 articles (01/2013 - 12/2004)|
|10.||Araie, Makoto: 2 articles (10/2005 - 12/2002)|
02/01/1993 - "In conclusion, UF-021 ophthalmic solution is extremely useful for the treatment of glaucoma."
01/01/1991 - "The present study suggests that UF-021 has potential as a safe and effective ocular hypotensive drug with a mechanism of action different from other drugs currently available for the treatment of glaucoma."
01/01/2014 - "An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy."
03/01/2013 - "Isopropyl unoprostone (IU), a maxi-K channel activator, is used topically to treat glaucoma, and has been reported to have neuroprotective effects on retinal neurons in vitro and in vivo. "
06/01/2006 - "Twenty-eight patients with unilateral or bilateral glaucoma were treated with Rescula instead of the original beta-blocker therapy. "
|2.||Open-Angle Glaucoma (Glaucoma, Open Angle)
11/01/2005 - "The efficacy of unoprostone isopropyl as an adjunct to topical beta-blocker in patients with open angle glaucoma: a-6-month study."
06/01/2006 - "Rescula achieved a significant (p = 0.00001) and long-lasting reduction in IOP (from 20.78 +/- 2.71 to 17.14 +/- 2.70 mmHg) in patients with open-angle glaucoma after 12 months of follow-up. "
11/01/2005 - "Topical unoprostone isopropyl beneficially provides additive IOP lowering effect to topical beta-blocker in patients with primary open angle glaucoma. "
11/01/2005 - "To assess the efficacy and safety of unoprostone isopropyl as an adjunctive treatment to topical beta-blocker in patients with primary open angle glaucoma (POAG). "
01/01/2001 - "To investigate the clinical characteristics of docosanoid derivative, isopropyl unoprostone in the treatment of primary open angle glaucoma (POAG). "
|3.||Retinitis Pigmentosa (Pigmentary Retinopathy)
05/01/2014 - "Therapeutic efficacy of topical unoprostone isopropyl in retinitis pigmentosa."
06/01/2013 - "Erratum to: Topical Isopropyl Unoprostone for Retinitis Pigmentosa: Microperimetric Results of the Phase 2 Clinical Study."
12/01/2012 - "Topical isopropyl unoprostone for retinitis pigmentosa: microperimetric results of the phase 2 clinical study."
05/01/2014 - "To evaluate the therapeutic effect of topical unoprostone isopropyl (unoprostone) on patients with retinitis pigmentosa (RP). "
12/01/2012 - "The purpose of this study was to determine whether topical 0.15% isopropyl unoprostone (IU), a BK-channel activator, could improve or maintain the central retinal sensitivity in patients with middle- to late-stage retinitis pigmentosa (RP). "
|4.||Ocular Hypertension (Glaucoma, Suspect)
01/01/2013 - "This review provides background information on unoprostone isopropyl (unoprostone), a prostanoid and synthetic docosanoid approved for the treatment of open-angle glaucoma and ocular hypertension, and recapitulates safety and efficacy data as it relates to this indication. "
12/01/2004 - "To determine the mechanism by which 0.15% unoprostone isopropyl reduces intraocular pressure (IOP) by studying 33 patients with ocular hypertension or primary open-angle glaucoma. "
01/01/2002 - "Safety of unoprostone isopropyl as mono- or adjunctive therapy in patients with primary open-angle glaucoma or ocular hypertension."
12/01/2002 - "A comparative clinical study of latanoprost and isopropyl unoprostone in Japanese patients with primary open-angle glaucoma and ocular hypertension."
01/01/2002 - "This review summarises the safety of unoprostone isopropyl (both at the 0.12 and 0.15% concentrations) instilled twice daily in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH). "
|5.||Low Tension Glaucoma
07/01/2005 - "To evaluate the effect of unoprostone isopropyl on microcirculation in the optic nerve head (ONH) of controls and patients with normal-tension glaucoma (NTG). "
07/01/2005 - "Effect of topical unoprostone isopropyl on optic nerve head circulation in controls and in normal-tension glaucoma patients."
02/01/2001 - "Unoprostone isopropyl did not induce any alterations in ocular hemodynamics in this pilot study with vasospastic normal-tension glaucoma patients."
02/01/2001 - "Because intraocular pressure-lowering agents should have a good safety profile with regard to ocular hemodynamics, the innocuousness of unoprostone isopropyl 0.15% with regard to ocular hemodynamics in vasospastic patients with normal-tension glaucoma was assessed in a pilot study. "
02/01/2001 - "An evaluation of the effect of unoprostone isopropyl 0.15% on ocular hemodynamics in normal-tension glaucoma patients."
|1.||Carbonic Anhydrase Inhibitors
|2.||isopropyl unoprostone (Rescula)
|10.||Synthetic Prostaglandins (Prostaglandin Analogues)
|1.||Intraocular Lens Implantation
|2.||Drug Therapy (Chemotherapy)